Akero Therapeutics Inc

Akero Therapeutics — Investor Presentation (September 2021)

40 slides from Akero Therapeutics's investor presentation, Sep 9, 2021

  1. Slide 1: A Global Disease, A Pioneering Treatment

    A Global Disease, A Pioneering Treatment Corporate Presentation September 2021

  2. Slide 2: Corporate Highlights

    - CONFIDENTIAL - CORPORATE HIGHLIGHTS 2 • Human FGF21 analog addresses all core aspects of NASH pathology • Engineered for optimal activity and convenient once - weekly dosing • We believe Phase 2a BALANCED study results in biopsy - confirmed NASH patients among strongest data in field for both F1 -

  3. Slide 3: Extensive Development and Commercialization Experience

    - CONFIDENTIAL - Tim Rolph, D.Phil | Co - Founder & Chief Scientific Officer • Over 30 years at Pfizer & Glaxo • CSO of Pfizer’s cardiovascular and metabolic disease unit • Head of Groton & UK Discovery Research, Pfizer • Major role in discovery and early clinical evaluation of two medicines: Selzen

  4. Slide 4: NASH: A Serious and Debilitating Multi-System Disease

    - CONFIDENTIAL - NASH: A SERIOUS AND DEBILITATING MULTI - SYSTEM DISEASE 4 An estimated 17 million Americans have NASH, with expectation that population will grow >50% by 2030 A GROWING HEALTH EPIDEMIC The number of NASH patients with advanced - stage fibrosis and cirrhosis is predicted to grow to 8

  5. Slide 5: Cirrhotic NASH Patients Have Poor Prognosis

    - CONFIDENTIAL - 5 CIRRHOTIC NASH PATIENTS HAVE POOR PROGNOSIS ~60% 5 - year mortality for F4 NASH patients absent transplant 0 5 10 15 20 25 30 F0 F1 F2 F3 F4 Liver - related mortality rate increases substantially from F3 to F4 fibrosis Liver - Related Mortality 0 .3 0 .6 4.3 7.9 23.3 Fibrosis Stag

  6. Slide 6: EFX Engineering Potentially Optimal for NASH Efficacy

    - CONFIDENTIAL - EFX ENGINEERING POTENTIALLY OPTIMAL FOR NASH EFFICACY, WITH CONVENIENT ONCE - WEEKLY DOSING 6 Key attributes Stanislaus, S et al. (2017) Endocrinology 158(5): 1314 - 27; Lee, S et al. (2018) Nature 553: 501 - 505; Kharitonenkov, A et al. (2007) Endocrinology 148(2)774 - 781 Akero pr

  7. Slide 7: EFX Acts on Two Major Sources of Liver Fat

    - CONFIDENTIAL - EFX ACTS ON TWO MAJOR SOURCES OF LIVER FAT WITH POTENTIAL FOR OPTIMAL REDUCTION 7 Source of Liver Fat FGF Receptor EFX Activity Lipolysis FGFR1c x De Novo Lipogenesis FGFR2c FGFR3c x Sources of Fat Flowing into and Through Liver for NASH Patients Adipose Tissue: Lipolysis (40 - 50%)

  8. Slide 8: EFX Direct and Indirect Anti-Fibrotic Effects

    - CONFIDENTIAL - EFX DIRECT AND INDIRECT ANTI - FIBROTIC EFFECTS 8 Myofibrobl asts *Cited literature available on company website Bao, L et al. (2018) Br J Pharmacol 175:3379 - 3393; Fisher, FM et al. (2014) Gastroenterology 147:1073 - 1083.e6; Jimenez, V et al. (2018) EMBO Mol Med 10:e8791; Lee, JH

  9. Slide 9: Phase 2a Trial (BALANCED) Design (F1-F3 NASH)

    - CONFIDENTIAL - Screening Biopsy - Confirmed NASH Randomization 70mg EFX (n=20) 50mg EFX (n=20) 28mg EFX (n=20) Placebo (n=20) Safety Follow - Up Responder Paired Biopsies Week 6 Week 12 Screening Post - Treatment 16 WEEKS Subjects achieving ≥30% relative reduction of hepatic fat at week 12 eligibl

  10. Slide 10: Phase 2a Expansion Cohort C Trial Design (F4 NASH)

    - CONFIDENTIAL - * PHASE 2A EXPANSION COHORT C TRIAL DESIGN (F4 NASH) 10 Primary Endpoint Safety & tolerability BALANCED study included an expansion cohort, Cohort C, of patients with compensated cirrhosis (F4), Child - Pugh Class A; results to inform subsequent development in cirrhotic patients 16

  11. Slide 11: Baseline Demographics: Main Study & Cohort C

    - CONFIDENTIAL - BASELINE DEMOGRAPHICS: MAIN STUDY & COHORT C BALANCED Main Study a Cohort C b Parameter Mean Placebo (N=21) EFX 28mg (N=19) EFX 50mg (N=20) EFX 70mg (N=20) Placebo (N=10) EFX 50mg (N=20) Age (Years) 52 50 53 53 57.1 61.1 Sex (Male/Female) 6/15 9/10 10/10 9/11 7/3 4/16 Weight (kg) 99

  12. Slide 12: High Rates of Fibrosis Improvement Across All Dose Groups (F1-F3)

    - CONFIDENTIAL - HIGH RATES OF FIBROSIS IMPROVEMENT AFTER 16 WEEKS ACROSS ALL DOSE GROUPS (F1 - F3 NASH) 12 Source Data: Liver Biopsy Evaluable Analysis Set, F1 - F3 (all BALANCED main study responders who had baseline and end - of - treatmen t liver biopsy results) 0% 10% 20% 30% 40% 50% 60% 70% Ov

  13. Slide 13: Fibrosis Improvement in F2-F3 Patients

    - CONFIDENTIAL - 9% 23% 68% Improved No Change Worsened 9% 23% 68% 2 13 FIBROSIS IMPROVEMENT IN F2 - F3 PATIENTS: HALF OF PATIENTS IMPROVED 2 STAGES All EFX Patients (n=40) Baseline F2 - F3 EFX Patients (n=22) 2 - Stage Improvement (n=11, 50%) 1 - Stage Improvement (n=4, 18%) 10% 35% 55% Source Data

  14. Slide 14: Fibrosis Improvement Among Cirrhotic Patients (F4 NASH)

    - CONFIDENTIAL - HIGH RATE OF FIBROSIS IMPROVEMENT AFTER ONLY 16 WEEKS AMONG CIRRHOTIC PATIENTS (F4 NASH) 14 Source Data: Liver Biopsy Analysis Set, F4; Topline preliminary data 1 No increase in NAS for ballooning, inflammation, or steatosis 2 Study not powered to assess statistical significance of

  15. Slide 15: Rapid Improvements in Fibrosis Biomarkers (F1-F3)

    - CONFIDENTIAL - -50% -40% -30% -20% -10% 0% 10% BL W1 W4 W8 W12 Placebo 28mg 50mg 70mg *** *** *** Pro - C3, LS Mea n Change from Baseline RAPID IMPROVEMENTS IN FIBROSIS BIOMARKERS CONSISTENT WITH HISTOLOGICAL IMPROVEMENTS (F1 - F3 NASH) 15 Enhanced Liver Fibrosis (ELF) Score, LS Mean *** p<0.001,

  16. Slide 16: Improvements in Fibrosis Biomarkers in Cirrhotic Patients (F4)

    - CONFIDENTIAL - IMPROVEMENTS IN FIBROSIS BIOMARKERS IN CIRRHOTIC NASH PATIENTS SUPPORT HISTOLOGY RESULTS (F4 NASH) Source Data: Biomarker Analysis Set, F4 (all Cohort C subjects with baseline and interpretable on - study measure of ELF or pro - C3 , respectively); Liver Stiffness Analysis Set, F4 (

  17. Slide 17: High Response Rates on NASH Resolution (F1-F3)

    - CONFIDENTIAL - HIGH RESPONSE RATES ON NASH RESOLUTION AFTER 16 WEEKS ACROSS ALL DOSE GROUPS (F1 - F3 NASH) 17 Source Data: Liver Biopsy Evaluable Analysis Set, F1 - F3 1 NAS score of 0 or 1 for lobular inflammation and a score of 0 for ballooning 2 Secondary and exploratory histological endpoints

  18. Slide 18: NASH Resolution Also Observed in Cirrhotic Patients (F4)

    - CONFIDENTIAL - NASH RESOLUTION ALSO OBSERVED IN CIRRHOTIC PATIENTS (F4 NASH) 18 0% 10% 20% 30% Overall 1 NAS score of 0 or 1 for lobular inflammation and a score of 0 for ballooning 2 Study not powered to assess statistical significance of histological endpoints NASH Resolution 1,2 Placebo n =5 0%

  19. Slide 19: Substantial Reductions in Liver Fat (F1-F3)

    - CONFIDENTIAL - SUBSTANTIAL REDUCTIONS IN LIVER FAT AT WEEK 12 ACROSS ALL DOSE GROUPS (F1 - F3 NASH) 19 Source Data: Full Analysis Set, F1 - F3 -15 -12 -9 -6 -3 0 Placebo 28mg 50mg 70mg - 0% - 12.3 *** - 13.4 *** - 14.1 *** Absolute Reduction (%) *** p<0.001, versus placebo (ANCOVA) LS Mean Reducti

  20. Slide 20: Substantial Reductions in Markers of Liver Injury

    - CONFIDENTIAL - -60% -40% -20% 0% 20% 40% BL W1 W4 W8 W12 W16 W20 Placebo 28 mg 50 mg 70 mg *** *** *** *** *** *** -60% -40% -20% 0% 20% 40% BL W1 W4 W8 W12 W16 W20 Placebo 28mg 50mg 70mg *** *** *** *** ** ** *** *** *** ALT, LS Mean Change from Baseline SUBSTANTIAL REDUCTIONS IN MARKERS OF LIVER

  21. Slide 21: Weight Loss Observed for All Dose Groups

    - CONFIDENTIAL - -4 -3 -2 -1 0 W16 70mg -4 -3 -2 -1 0 BL W1 W4 W8 W12 W16 Placebo 28mg 50mg 70mg Mean Change in Body Weight (kg) 21 WEIGHT LOSS OBSERVED FOR ALL DOSE GROUPS (F1 - F3 NASH) Mean Change in Body Weight at Week 16 (kg) Source Data: Full Analysis Set, F1 - F3 Placebo 28mg 50mg - 0.3 - 2.3

  22. Slide 22: Improved Lipoprotein Profile (F1-F3 NASH)

    - CONFIDENTIAL - -20% -15% -10% -5% 0% W16 - 16% - 2% - 6% 0% * Placebo 28mg 50mg 70mg -25% -20% -15% -10% -5% 0% W16 - 22% - 15% - 17% - 1% *** * ** Placebo 28mg 50mg 70mg 0% 10% 20% 30% 40% 50% W16 + 34% + 39% + 41% + 4% *** *** *** Placebo 28mg 50mg 70mg IMPROVED LIPOPROTEIN PROFILE (F1 - F3 NASH

  23. Slide 23: Clinically Meaningful Improvements in Glycemic Control

    - CONFIDENTIAL - -0.9 -0.8 -0.7 -0.6 -0.5 -0.4 -0.3 -0.2 -0.1 0.0 0.1 W16 CLINICALLY MEANINGFUL IMPROVEMENTS IN GLYCEMIC CONTROL AFTER 16 WEEKS (F1 - F3 NASH) 23 LS Mean Change From Baseline to Week 16 (%) 1 Absolute change from baseline, % Type 2 DM Patients (N=41) + 0.1 - 0.6 - 0.9 + 0.0 Placebo 2

  24. Slide 24: Interpreting the Rapid Reversal of Fibrosis Observed with EFX

    - CONFIDENTIAL - 24 INTERPRETING THE RAPID REVERSAL OF FIBROSIS OBSERVED IN NASH PATIENTS TREATED WITH EFX Indirectly anti - fibrotic Directly anti - fibrotic ↓ Hepatocyte Stress ↓ Inflammation ↓ Liver fat ↓ Collagen Synthesis EFX • Addressing underlying NASH disease drivers may indirectly contribut

  25. Slide 25: Drug-Related Treatment-Emergent Adverse Events (F1-F3 NASH)

    - CONFIDENTIAL - DRUG - RELATED TREATMENT - EMERGENT ADVERSE EVENTS (TEAE) (F1 - F3 NASH) Most Frequent (>10%) Drug - Related AEs * Placebo (N=21) All EFX (N=58) EFX 28mg (N=19) EFX 50mg (N=19) EFX 70mg (N=20) Diarrhea 2 (10%) 21 (36%) 5 (26%) 10 (53%) 6 (30%) Nausea 0 (0%) 20 (34%) 6 (32%) 4 (21%)

  26. Slide 26: Tolerability Overview (F4 NASH)

    - CONFIDENTIAL - Key Observations • Encouraging tolerability given population with more advanced disease • All injection site AEs Grade 1 • No reports of tremor TOLERABILITY OVERVIEW (F4 NASH) Most Frequent (>15%) Drug - Related AEs Placebo (N=10) EFX 50mg (N=17) Diarrhea 1 (10%) 7 (41%) Nausea 1 (1

  27. Slide 27: NASH Development Landscape: Fibrosis Improvement (F1-F3)

    - CONFIDENTIAL - NASH DEVELOPMENT LANDSCAPE: FIBROSIS IMPROVEMENT (F1 - F3) 27 Proportion of Subjects with ≥1 Stage Improvement in Fibrosis and No Worsening of NAS 1 1 FDA Guidance for Industry: Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatment (201 8) Not

  28. Slide 28: EFX Path to Phase 3: Parallel 2b Trials in F2/F3 & F4

    - CONFIDENTIAL - EFX PATH TO PHASE 3: PARALLEL 2B TRIALS IN F2/F3 & F4 BALANCED Cohort C (Expansion of BALANCED) HARMONY SYMMETRY Status Completed (Readout Jun’20) Completed (Readout Mar’21) Readout expected in 3Q’22 Initiated Jul’21 Duration 16 Weeks 16 Weeks 24 Weeks 36 Weeks EFX Arms 28, 50, 70mg

  29. Slide 29: HARMONY Trial Design: Non-Cirrhotic NASH (F2/F3)

    - CONFIDENTIAL - HARMONY TRIAL DESIGN: NON - CIRRHOTIC NASH (F2/F3) Screening Randomization EFX 28mg Placebo 24 Weeks EFX 50 mg Placebo EFX * Long - Term Safety Follow - Up Phase 2b Liver Biopsy * Phase 3 protocol finalization expected after end - of - Phase 2 meeting with FDA Key Inclusion Criteria

  30. Slide 30: SYMMETRY Trial Design: Cirrhotic NASH (F4)

    - CONFIDENTIAL - SYMMETRY TRIAL DESIGN: CIRRHOTIC NASH (F4) Screening Randomization EFX 28mg Placebo 36 Weeks EFX 50 mg Placebo EFX * Long - Term Safety Follow - Up Phase 2b Liver Biopsy * Pending finalization of Phase 3 protocol Key Inclusion Criteria • F4 NASH Phase 2b Primary Endpoint • Fibrosis

  31. Slide 31: Strong Financial Position

    - CONFIDENTIAL - 31 STRONG FINANCIAL POSITION COMPLETED UPSIZED IPO June 20, 2019 $ 16 /share Priced upsized IPO at top of marketing range ~$ 106M Raised in aggregate gross proceeds CASH (1) ON HAND As of June 30, 2021 ~$ 230M (1) Cash, cash equivalents and short - term marketable securities COMPLET

  32. Slide 32: Backup Slides

    Backup Slides

  33. Slide 33: Patient Disposition (BALANCED Main Study)

    - CONFIDENTIAL - 33 PATIENT DISPOSITION (BALANCED MAIN STUDY) Randomized (80) MRI - PDFF Responders (50) (≥ 30% Relative Reduction) Week 12 MRI - PDFF (68) End - of - Treatment Biopsies Collected (42) Randomized Not Dosed EFX (1) Discontinued (11) Non - Responders Placebo (18) Dosed (79) Due to AEs

  34. Slide 34: Cirrhosis Regression Is Associated with Improved Clinical Outcomes

    - CONFIDENTIAL - 34 CIRRHOSIS REGRESSION IS ASSOCIATED WITH IMPROVED CLINICAL OUTCOMES Pooled treatment groups from STELLAR 4 and s imtuzumab cirrhosis study 7.2 8.3 1.1 0.7 0 1 2 3 4 5 6 7 8 9 NASH CRN fibrosis stage Ishak fibrosis stage No fibrosis regression Fibrosis regression 69/957 69/834 2/17

  35. Slide 35: Improved Glycemic Control; Trend Toward Weight Loss (F4 NASH)

    - CONFIDENTIAL - 0% 25% 50% 75% 100% 1 -25% -20% -15% -10% -5% 0% 1 -0.5 -0.4 -0.3 -0.2 -0.1 0.0 0.1 0.2 0.3 CFB - 0.4 +0.1 IMPROVED GLYCEMIC CONTROL; TREND TOWARD WEIGHT LOSS (F4 NASH) 35 Adiponectin 2 C - Peptide 2 LS Mean Change From Baseline to Week 16 (%) ** p<0.01, versus placebo (ANCOVA) Sour

  36. Slide 36: FGF21 Development Landscape

    - CONFIDENTIAL - FGF21 DEVELOPMENT LANDSCAPE Noninvasive Measures: Percent Change From Baseline to End of Study Akero (EFX) 16 weeks BMS ( Pegbelfermin ) 16 weeks 89Bio (BIO89 - 100) 12 weeks Dose pbo 28 QW 50 QW pbo 20 QW 10 QD pbo 18 QW 27 QW 36 Q2W Patient Population Biopsy - confirmed NASH Biops

  37. Slide 37: FGF21 Development Landscape: Summary

    - CONFIDENTIAL - 37 FGF21 DEVELOPMENT LANDSCAPE: SUMMARY Consideration Fc - FGF21 Fusion Protein (Akero) Pegylated FGF21 (BMS or 89Bio) Patient Population: NASH diagnosed only by biopsy; NASH patients have more advanced disease and worse comorbidities Biopsy - confirmed NASH BMS: biopsy - confirmed

  38. Slide 38: Cohort C Results in Context: Fibrosis Improvement (F4)

    - CONFIDENTIAL - Belapectin 52 Wks (Ph2b) Oral GAL - 3 COHORT C RESULTS IN CONTEXT: FIBROSIS IMPROVEMENT * (F4) Selonsertib 48 Wks (Ph3) Oral Simtuzumab 96 Wks (Ph2b) IV infusion ASK - 1 ACC FXR LOXL2 Firsocostat 48 Wks (Ph2b) Oral Cilofexor 48 Wks (Ph2b) Oral (n=20) (n=21) Pbo 20mg Efruxifermin 16

  39. Slide 39: NASH Development Landscape: NASH Resolution (F1-F3)

    - CONFIDENTIAL - Pbo 0.8g 1.2g Pbo All EFX 50mg (N=2) (N=13) 48% 54 % (N=40) * 50 % * NASH DEVELOPMENT LANDSCAPE: NASH RESOLUTION (F1 - F3) 39 Proportion of Subjects with Resolution of NASH and No Worsening of Fibrosis 1 1 FDA Guidance for Industry: Noncirrhotic Nonalcoholic Steatohepatitis With Liv

  40. Slide 40: A Global Disease, A Pioneering Treatment

    A Global Disease, A Pioneering Treatment NASDAQ: AKRO

Akero Therapeutics — Investor Presentation (September 2021) on 6ix